drugset

drugset / Trial / NCT02328261

A Phase II Study of Icotinib in Treating Patients With Advanced Nasopharyngeal Carcinoma

NCT02328261 ↗

Phase 2 Unknown 66 enrolled Betta Pharmaceuticals Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is a phase 2 study to evaluate the efficacy of single-agent icotinib in patients with advanced nasopharyngeal carcinoma.

Timeline

Start: 2014-11
Primary completion: 2016-10
Completion: 2017-04

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Icotinib	Small molecule	125 mg	Oral

Indications